(secondQuint)Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis.

 Patients will receive initial intravenous (IV) echinocandin therapy.

 Patients who are eligible for randomization will receive SCY-078 500-mg orally, SCY-078 750-mg orally, or standard-of-care.

.

 Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis@highlight

The purpose of this study is to compare the safety, pharmacokinetics, and efficacy of oral SCY-078 vs.

 standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis.

